Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PH-6
- Development stage
- Preclinical
- Lead developer
- Akari Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
PH-6 is a proprietary cytotoxic toxin platform developed by Peak Bio to serve as a payload for antibody-drug conjugates (ADCs). It is part of Peak Bio's portfolio of ADC technologies, which also includes the PH-1 splicing modulator and the PH-5 toxin platform. PH-6 is designed to be chemically linked to targeting antibodies, allowing for the selective delivery of the cytotoxic agent to malignant cells while sparing healthy tissue. While the specific molecular target of the PH-6 toxin (such as DNA or microtubules) has not been publicly disclosed, it is utilized in the company's discovery and preclinical oncology pipeline to create next-generation targeted cancer therapies.
- Other names
- PH-6 toxin platformPH6 toxin platformPH 6 toxin platformPH-6 payloadPH6 payloadPH 6 payload
Beyond the preview
Go deeper on PH-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PH-6.